| Similar Articles |
|---|
 |
The Motley Fool
April 8, 2004
Charly Travers |
Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.   |
The Motley Fool
December 14, 2004
Charly Travers |
A Stagnant Drug Stock A drug launch is not driving share price increases for Indevus. |
The Motley Fool
August 8, 2007
Brian Orelli |
Is Indevus Headed to the Black? Two new drugs should help turn things around at specialty pharmaceutical company Indevus. The company is not in the black yet, but they have been on a roll these last three months with FDA approvals of two new drugs. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
September 29, 2008
Brian Orelli |
An Overnight 2-Bagger A nod from the FDA and a new partnership boost Indevus shares. Where to, now? |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
